Novo Nordisk India rolls-out a once-weekly basal insulin Awiqli
Novo Nordisk has launched Awiqli, a once-weekly basal insulin for diabetes patients, in the Indian market. The product aims to simplify treatment regimens, though medical experts advise caution regarding its real-world application for Type 1 diabetes.
Why it matters
This innovation represents a significant shift in diabetes management, potentially improving patient compliance through reduced injection frequency.
Danish healthcare company Novo Nordisk is rolling out its Awiqli – a weekly once basal insulin, for adults with Type 1 or Type 2 diabetes mellitus, in India. The product reduces the insulin regimen from once-daily to once-weekly – or from 365 shots to 52.
The article balances corporate product news with expert medical perspectives.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in